BeiGene, Ltd. BGNE
Set alert
184.71 0.00 0.00%
At close · Dec 31
183.91 Day range 187.42
52-week range unavailable
- YTD
- +4.67%
- 1 year
- +4.67%
- Open
- 184.00
- Prev close
- 184.71
- Mkt cap
- 20.21B
- Vol
- 329.40K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 183.91
- High
- 187.42
2Y chart
Signals (116)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Dec 27, 2024 | 1 year ago |
| SMA: Bullish | Dec 24, 2024 | 1 year ago |
| SMA: Bearish | Dec 18, 2024 | 1 year ago |
| SMA: Bullish | Dec 17, 2024 | 1 year ago |
| SMA: Bearish | Dec 16, 2024 | 1 year ago |
| MACD: Sell Signal | Dec 11, 2024 | 1 year ago |
| SMA: Bearish | Dec 2, 2024 | 1 year ago |
| SMA: Bullish | Nov 29, 2024 | 1 year ago |
| MACD: Buy Signal | Nov 27, 2024 | 1 year ago |
| SMA: Bearish | Oct 30, 2024 | 2 years ago |
| MACD: Sell Signal | Oct 14, 2024 | 2 years ago |
| RSI: Overbought | Oct 9, 2024 | 2 years ago |
| RSI: Overbought | Sep 30, 2024 | 2 years ago |
| MACD: Buy Signal | Sep 25, 2024 | 2 years ago |
| RSI: Overbought | Sep 11, 2024 | 2 years ago |
| MACD: Sell Signal | Aug 29, 2024 | 2 years ago |
| RSI: Overbought | Aug 26, 2024 | 2 years ago |
| RSI: Overbought | Aug 8, 2024 | 2 years ago |
| SMA: Bullish | Aug 5, 2024 | 2 years ago |
| SMA: Bearish | Aug 1, 2024 | 2 years ago |
Newest 20 of 116.
Financials — quick view
BGNE Revenue — quarterly 1.00B
BGNE Net income — quarterly -121.35M
BGNE EPS — quarterly -0.09
News
- Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
- President Trump demands drugmakers slash prices within 60 days
- BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Nasopharyngeal Cancer
- BeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid Tumors
- BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA's Leadership and Next-Generation Innovation
- BeiGene to Present at the RBC Capital Markets Global Healthcare Conference
- Undercovered Dozen: Richtech Robotics, Intesa Sanpaolo, BeiGene, Analog Devices +
- BeiGene, Ltd., Soon To Be BeOne Medicines: New Name And New Profit
- BeiGene, Ltd. (ONC) Q1 2025 Earnings Call Transcript
- Chinese Biotech BeiGene Stock Falls Despite Strong Brukinsa Sales And Earnings Beat
Your note
Sign in to keep a note on BGNE — it syncs with the Stock Master app.